Business Description
Prescient Therapeutics Ltd
NAICS : 325412
ISIN : AU000000PTX3
Description
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 247.24 | |||||
Equity-to-Asset | 0.94 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -26 | |||||
3-Year EPS without NRI Growth Rate | -4.6 | |||||
3-Year FCF Growth Rate | -14.5 | |||||
3-Year Book Growth Rate | -11.7 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 30.3 | |||||
9-Day RSI | 35.5 | |||||
14-Day RSI | 39.69 | |||||
3-1 Month Momentum % | 41.03 | |||||
6-1 Month Momentum % | 25 | |||||
12-1 Month Momentum % | 17.02 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 15.97 | |||||
Quick Ratio | 15.97 | |||||
Cash Ratio | 8.99 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.9 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -37.65 | |||||
ROA % | -34.35 | |||||
ROIC % | -165.81 | |||||
3-Year ROIIC % | 1189.35 | |||||
ROC (Joel Greenblatt) % | -254.29 | |||||
ROCE % | -39.39 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.32 | |||||
Price-to-Tangible-Book | 2.2 | |||||
EV-to-EBIT | -3.66 | |||||
EV-to-EBITDA | -3.66 | |||||
EV-to-FCF | -2.79 | |||||
Price-to-Net-Current-Asset-Value | 2.2 | |||||
Price-to-Net-Cash | 4.4 | |||||
Earnings Yield (Greenblatt) % | -27.32 | |||||
FCF Yield % | -27.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Prescient Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil A$) | |||
EPS (TTM) (A$) | -0.009 | ||
Beta | 0.16 | ||
3-Year Sharpe Ratio | -0.49 | ||
3-Year Sortino Ratio | -0.7 | ||
Volatility % | 49.24 | ||
14-Day RSI | 39.69 | ||
14-Day ATR (A$) | 0.002521 | ||
20-Day SMA (A$) | 0.0489 | ||
12-1 Month Momentum % | 17.02 | ||
52-Week Range (A$) | 0.037 - 0.066 | ||
Shares Outstanding (Mil) | 805.32 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Prescient Therapeutics Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Prescient Therapeutics Ltd Stock Events
Event | Date | Price (A$) | ||
---|---|---|---|---|
No Event Data |
Prescient Therapeutics Ltd Frequently Asked Questions
What is Prescient Therapeutics Ltd(ASX:PTX)'s stock price today?
The current price of ASX:PTX is A$0.04. The 52 week high of ASX:PTX is A$0.07 and 52 week low is A$0.04.
When is next earnings date of Prescient Therapeutics Ltd(ASX:PTX)?
The next earnings date of Prescient Therapeutics Ltd(ASX:PTX) is .
Does Prescient Therapeutics Ltd(ASX:PTX) pay dividends? If so, how much?
Prescient Therapeutics Ltd(ASX:PTX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |